Piper Jaffray said in a note Monday that Gilead Sciences (GILD) likely won't be impacted by GlaxoSmithKline's (GSK) potential new two-drug HIV regimen.
Citigroup analysts say IMS Health (IMS) data show that Gilead's (GILD) hepatitis-C drug sales may be below forecasts.
Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.